Patients with germline mutations in homologous DNA recombination repair (HRR) genes, such as BRCA1, BRCA2, ATM, PALB2, and CHEK2, are at a higher risk of prostate cancer development and usually have worse prognosis [21]. This evidence concerns the gene BRCA2 and prostate carcinoma.